Globus Medical
GMED
73.75
-2.68
-3.51%
Globus Medical
US · GMED
#1454 by market cap
Listed 1970
73.75
-2.68
-3.51%
Live - 5344 symbols - heartbeat 14s ago
· 2026-10-08 07:16
Pre-market
73.50
-0.34%
After-hours
76.00
+3.05%
- Market cap
- 9.90B
- P/E (TTM)i
- 18.86
- P/Bi
- 2.08
- EPSi
- 3.92
- Div yieldi
- 0.00%
- 52W posi
- 38%
Reader sentiment
Are you bullish or bearish on GMED?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.2 percentage points.
Institutional ownership
- Held by institutions
- 90.23% +0.18pp
- Institutions
- 692 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund76.89%
Individual/Insider17.18%
Hedge Fund6.25%
Public Company2.63%
Government Pension Fund1.58%
Private Company1.06%
Sovereign Wealth Fund0.85%
Insurance Company0.48%
VC/PE Fund0.20%
Top holders as of 2026-03-31
David Paul
16.62% · 22.32M sh
BlackRock
8.05% · 10.81M sh
Janus Henderson Group plc
6.11% · 8.20M sh
Vanguard Capital Management, LLC
4.34% · 5.82M sh
Vanguard Portfolio Management, LLC
3.72% · 4.99M sh
Kayne Anderson Rudnick Investment Management, LLC
3.19% · 4.28M sh
Invesco Ltd.
3.03% · 4.07M sh
State Street Global Advisors
2.77% · 3.71M sh
Sculptor Capital Management, Inc.
2.23% · 3.00M sh
J.P. Morgan Asset Management, Inc.
1.93% · 2.59M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 30 buys · 19 sells
| Name | Role | Stake |
|---|---|---|
| David Paul | Co-Founder & Executive Chairperson | 16.62% |
| David Davidar | Independent Director | 0.50% |
| Ann Rhoads | Independent Director | 0.03% |
| Daniel Wolterman | Director | 0.02% |
| Leslie Norwalk | Director | 0.01% |
| Robert Douglas | Independent Director | 0.00% |
| John DeFord | Director | -- |
| Stephen Zarrilli | Independent Director | -- |
| James Tobin | Independent Director | -- |
| Daniel Lemaitre | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-14 | James Tobin | Independent Director | Derivative Exercise and Sale | -30,000 | $53.75–74.58 |
| 2026-08-17 | Stephen Zarrilli | Independent Director | Derivative Exercise and Sale | -25,000 | $53.27–87.04 |
| 2026-07-26 | David Davidar | Independent Director | Other Disposition | -2,500 | -- |
| 2026-06-04 | David Davidar | Independent Director | Derivative Exercise and Sale | -25,000 | $26.27–80.76 |
| 2026-06-03 | Ann Rhoads | Independent Director | Derivative Exercise and Retained | +25,000 | $26.27 |
| 2026-04-13 | John DeFord | Director | Intent to Sell (Form 144) | -30,000 | $93.10 |
| 2026-02-24 | Kelly Huller | Senior Vice President | Derivative Exercise and Sale | -20,000 | $43.58–94.50 |
| 2026-02-11 | Kelly Huller | Senior Vice President | Derivative Exercise and Sale | -10,000 | $45.64–87.67 |
| 2026-01-20 | Ann Rhoads | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | John DeFord | Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Stephen Zarrilli | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | James Tobin | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | David Paul | Co-Founder & Executive Chairperson | Other Derivative Acquisition | +100,000 | $94.15 |
| 2026-01-20 | Daniel Wolterman | Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Robert Douglas | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | David Davidar | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Leslie Norwalk | Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Daniel Lemaitre | Independent Director | Other Derivative Acquisition | +15,000 | $94.15 |
| 2026-01-20 | Keith Pfeil | Senior Vice President | Other Derivative Acquisition | +100,000 | $94.15 |
| 2026-01-20 | Kelly Huller | Senior Vice President | Other Derivative Acquisition | +40,000 | $94.15 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:16:36 · For reference only, not investment advice and not tailored to your situation.